Goldberg Jeffrey L

Discovery and clinical translation of novel glaucoma biomarkers.

Here we review recent progress in the development of novel biomarkers for glaucoma in the context of disease pathophysiology and we propose future steps for the field, including integration of exploratory biomarker outcomes into prospective therapeutic trials.

SALT Trial: Steroids after Laser Trabeculoplasty: Impact of Short-Term Anti-inflammatory Treatment on Selective Laser Trabeculoplasty Efficacy.

Significantly better IOP reduction at 12 weeks was measured in eyes treated with steroid or NSAID drops after SLT.

Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes.

Use of rhNGF is safe and tolerable in a topical 180-μg/mL formulation.

Preferential Loss of Contrast Decrement Responses in Human Glaucoma.

The observed pattern of preferential loss of decremental responses in human glaucoma is consistent with prior reports of selective damage to OFF retinal ganglion cells in murine models and in data from human ERG and retinal imaging.

Structural and Metabolic Imaging After Short-term Use of the Balance Goggles System in Glaucoma Patients: A Pilot Study.

There were no significant changes observable using conventional OCT imaging after short-term use of the BGS, although metabolic imaging using FPF may be a useful potential biomarker to complement existing investigations.

Corrigendum to Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes. Am J Ophthalmol 2022;234:223-234.

Glaucoma Classification Through SSVEP-Derived ON- and OFF-Pathway Features.

Our findings highlight the informational value of signal phase, a metric often omitted in applications of the SSVEP to glaucoma and other optic neuropathies.

Nicotinamide and Pyruvate in Open-Angle Glaucoma: A Randomized Controlled Trial on Neuroprotection-Design and Methodology.

This novel trial design may deliver valuable data on the neuroprotective potential of nicotinamide and pyruvate supplementation in glaucoma and improve our understanding of optimal study design for longitudinal randomized clinical trials focused on glaucoma neuroprotection.

HDAC4 Promotes Neuroprotection of Retinal Ganglion Cells After Optic Nerve Injury.

Enhancement of HDAC4 activity promotes RGC survival and axon regeneration in a model of RGC injury, normalizing RGC gene expression toward the uninjured state.

Impact of Type 2 diabetes mellitus and insulin use on progression to glaucoma surgery in primary open angle glaucoma.

Higher baseline HbA1c, particularly in patients taking insulin may be associated with higher rates of glaucoma surgery in POAG.

The Frequency of Optical Coherence Tomography Testing in Glaucoma at a Single Academic Medical Center.

The relative use of clinical examinations, VF testing, and OCT imaging varies among glaucoma diagnoses.